One recent paper in the Proceedings (1) and one in this issue (2) demonstrate that tumor immunogenicity can be enhanced by engineering the tumor cells to produce any one of several molecules known to play a role in the immune mechanism, a molecule that is not expressed or is underexpressed in the parental tumor. An important feature of these studies is that the induction of increased immunogenicity in the engineered cells results in an enhanced reaction against the unaltered parental cells, thus possibly opening the door to successful immunotherapy. Of course, before the age of genetic engineering, many less sophisticated methods had been used to increase the immunogenicity of tumor cells, and it remains to be seen whether these more modem approaches are of greater practical significance than the methods of the past. If nothing else, they do promise to give insight into the mechanisms of the enhanced immunogenicity.
It is now almost 40 years since it became apparent that many tumors are immunogenic, as judged by immunizationchallenge tests with transplanted tumors in syngeneic mice. During that time the immune mechanism has been extensively dissected, and, although much remains to be learned, the increase in understanding has been impressive. However, despite some limited indications of beneficial therapeutic effects, attempts to use the immune mechanism for therapy have been largely disappointing. It seems to me that the reasons for this disappointment reside in two separate features of the immune response to tumors, either or both of which may possibly be overcome by current studies such as those described in the two Proceedings papers (1, 2) .
The first feature that in my opinion may have helped to frustrate past attempts at immunotherapy was observed in the earliest modem studies of tumor immunity. Work in vitro and with syngeneic tumor implants in vivo has made it clear that many tumors possess antigens to which the host is reactive in transplantation and other tests, but, as Stutman (3) has pointed out, this immunogenicity is seldom realized during oncogenesis in a way that affects the incidence of de novo tumors; alteration of the immune capacities of the hosts seldom altered incidence. The juxtaposition of these facts points unmistakably to the critical role of the manner of antigen presentation. Excision of the primary de novo potentially immunogenic tumor and the subsequent challenge of that animal with that tumor showed little or no effect upon the growth of the challenge implant as compared with the growth of the same tumor in syngeneic controls. Thus, to show that a mouse could be immunized against implants of its own (i.e., autochthonous, methylcholanthrene-induced tumor), it was necessary to repeatedly immunize the animal with that tumor before giving the challenge implant (4); the temporary growth of the primary in situ untransplanted tumor did not of itself produce a detectable immunity to subsequent implants of the tumor. A number of experiments can be cited that make essentially the same point (5, 6 ). An animal (and by inference a human) is not appreciably immunized by the growth of its undisturbed de novo tumor even if the tumor is demonstrably immunogenic when transplanted to syngeneic hosts; furthermore, for one reason or another, the original host may be difficult to immunize as compared with secondary hosts-a point that needs further systematic study (4) . Nonetheless, the mouse work does show that the host can be immunized, perhaps only with difficulty, against its own native tumor; therefore, immunotherapy of at least some tumors would seem to be a possibility.
The second and (in the present context) probably more important feature of tumor immunity, one that may be fundamental in frustrating attempts at immunotherapy, was also observed at the very beginning of the modem era-namely, the lack of immunogenicity of so-called "spontaneous" tumors. It seems to be a general rule among animal tumors when the appropriate transplantation studies can be performed that the weaker an associated carcinogenic agent may be, the less immunogenicity on average the tumor will appear to possess. At the extremes, sarcomas induced with high dosages of the potent carcinogen 3-methylcholanthrene tended to be highly immunogenic with few exceptions, whereas those that arose spontaneously (i.e., without known contact with a carcinogenic agent) appeared to be nonimmunogenic (7). The effect seems to be independent of the immunodepressive effects of the carcinogen because similar results are obtained in vitro or when less than immunodepressive dosages of carcinogen are used (3, 8) . In my laboratory, a reproducible positive correlation was observed between the dosage of the chemical carcinogen and the average immunogenicities of the resulting sarcomas (9, 10) . Probably the most often cited paper illustrating the lack of immunogenicity of spontaneous rodent tumors is that of Hewitt, who studied 27 spontaneous mouse tumors and failed to detect immunogenicity in any one of them (11 (11) . However, I have reread this famous paper and have found that quite regularly the challenge tumors grew better, not worse as expected, in the immunized animals as compared with the controls or in the normal mice as compared with those that were immunocrippled by x-radiation. In fact, in seven of seven tumors tested for immunogenicity by immunization with lethally radiated tumor cells, the subsequent challenge implants grew markedly better in the immunized animals as compared with the nonimmunized controls! Hewitt noted this fact but dismissed the result as being caused by some type of inconsequential artifact (11); it was certainly not the anticipated result. I think the result indicates that in actuality the tumors were immunogenic, but the resulting immunity was low enough to cause immune stimulation rather than inhibition of the challenge implants. If one accepts the reality of the phenomenon of immune stimulation of tumor growth, the Hewitt data in my opinion go a long way toward the demonstration that spontaneous tumors are, in fact, immunogenic.
Although tumor immunostimulation has been well reviewed (12) (13) (14) , at this point a brief recapitulation of the evidence supporting the reality and importance of the phenomenon of the immune stimulation of tumor growth is probably in order. There are extensive data from many laboratories showing that, depending upon the circumstances, the immune reaction can be either inhibitory or stimulatory to the growth of tumor cells; in general, it seems that high levels of immune reactants of any type are inhibitory, but lower levels of the same reactants tend to be stimulatory (14) . According to the immune stimulation hypothesis, an intermediate-to-low but still positive level of immune reaction is required for immune stimulation of tumor to occur (14) . Therefore, to show a possible immune stimulation of tumor growth, it may be necessary to titrate the immune capacity. It is in the middle ofthe titration range that immune stimulation should be observed, and indeed, that is the case, as has been shown in several studies (15, 16 Under these confusing circumstances, it may not be surprising that immunotherapeutic manipulations, despite their great promise, have thus far produced inconsistent results. However, the probability that most and perhaps all tumors are potentially immunogenic implies that the genetic engineering of tumor cells to increase their immunogenicity, as was done in the two Proceedings papers (1, 2) , might be successful with most and perhaps all tumors and, therefore, that the next half century of tumor immunology may yield more practical benefits than has the last.
